

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Abstract 6262: Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/2010414> since 2024-09-05T06:52:59Z

*Publisher:*

AACR

*Published version:*

DOI:10.1158/1538-7445.am2022-6262

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



**Control/Tracking Number:** 22-A-4437-AACR

**Activity:** Abstract Submission

**Current Date/Time:** 12/16/2021 5:28:55 AM

**Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide**

**Author Block:** *Giovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, Filippo Pietrantonio, Alessio Amatu, Marco Macagno, Ludovic Barault, Andrea Cassingena, Alice Bartolini, Paolo Luraghi, Gianluca Mauri, Paolo Battuello, Nicola Personemi, Valeria Pessei, Pietro Paolo Vitiello, Federica Tosi, Laura Idotta, Emanuele Valtorta, Emanuela Bonoldi, Giovanni Germano, Federica Di Nicolantonio, Silvia Marsoni, Salvatore Siena, Alberto Bardelli.* University of Turin, Turin, Italy, Niguarda Cancer Center, Milan, Italy, The FIRC Institute of Molecular Oncology, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Candiolo Cancer Institute, FPO, Candiolo, Turin, Italy, Humanitas University, Milan, Italy

The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient (MMRp) and unresponsive to immunotherapy, while MMR deficient (MMRd) tumors often respond to immune checkpoint blockade (ICB). We previously reported that treatment of CRC preclinical models with temozolomide (TMZ) leads to MMR deficiency, increased tumor mutational burden (TMB) and, sensitization to immunotherapy. To clinically translate these findings, we designed the ARETHUSA clinical trial whereby O6-Methylguanine-DNA-methyltransferase (MGMT) deficient, MMR proficient and KRAS mutant mCRC patients receive priming therapy with TMZ. Analysis of solid tissue biopsies and circulating tumor DNA (ctDNA) obtained after TMZ treatment revealed the emergence of TMZ mutational signature, alterations in MMR genes and increased TMB in 14 out of 16 patients. Genetic mutations induced by TMZ were dose-dependent and multiple alterations in the nucleotide context favored by the TMZ signature emerged in MMR genes such as the MSH6 T1219I variant which was detected in ctDNA and tissue of 13/14 (93%) of the cases. A subset of the patients whose tumors after TMZ priming displayed the MSH6 mutation, the TMZ mutational signature and increased TMB, achieved disease stabilization upon pembrolizumab treatment. Overall, we provide *proof-of-concept* that treatment of MGMT deficient/MMR proficient KRAS mutant mCRCs with TMZ can be tracked by mutational signature analysis and lead to inactivation of the MMR pathway, emergence of the TMZ mutational signature, TMB increase, and, in some cases, to disease stabilization during ICB.

Author Disclosure Information:

**G. Crisafulli:** None. **A. Sartore-Bianchi:** ; A.S.B. is a member of advisory boards; Amgen. ; Amgen. ; Bayer. ; A.S.B. is a member of advisory boards; Bayer. ; A.S.B. is a member of advisory boards; Sanofi. ; Sanofi. ; Servier. ; A.S.B. is a member of advisory boards; Servier. ; A.S.B. is a member of advisory boards; Servier. ; **L. Lazzari:** None. **F. Pietrantonio:** ; F.P. received honoraria; Merck-Serono. ; Merck-Serono. ; Amgen. ; F.P. received honoraria; Amgen. ; F.P. received honoraria; Sanofi. ; Sanofi. ; Lilly. ; F.P. received honoraria; Lilly. ; F.P. received honoraria; Servier. ; Servier. ; Bayer. ; F.P. received honoraria; Bayer. ; F.P. received honoraria; Astrazeneca. ; Astrazeneca. ; BMS. ; BMS. **A. Amatu:** None. **M. Macagno:** None. **L. Barault:** ; Biocartis. ; Biocartis. **A. Cassingena:** None. **A. Bartolini:** None. **P. Luraghi:** None. **G. Mauri:** None. **P. Battuello:** None. **N. Personemi:** ; N.P. received consulting fees; Amgen. ; Amgen. ; Merck-Serono. ; N.P. received consulting fees and institutional research funding; Merck-Serono. ; N.P. received consulting fees and institutional research funding; Servier. ; Servier. ; AbbVie. ; N.P. received lectures fees; AbbVie. ; N.P. received lectures fees; Gilead. ; Gilead. ; Lilly. ; N.P. received lectures fees; Lilly. ; N.P. received lectures fees; Sanofi. ; Sanofi. ; ArQule. ; ArQule. ; N.P. received institutional research funding; Basilea. **V. Pessei:** None. **P. Vitiello:** None. **F. Tosi:** None. **L. Idotta:** None. **E. Valtorta:** None. **E. Bonoldi:** None. **G. Germano:** ; G.G. is cofounder and shareholder of NeoPhore; NeoPhore. ; NeoPhore. **F. Di Nicolantonio:** None. **S. Marsoni:** None. **S. Siena:** ; S.S. is an advisory board member; AstraZeneca. ; AstraZeneca. ; Bayer. ; S.S. is an advisory board member; Bayer. ; S.S. is an advisory board member; BMS. ; S.S. is an advisory board member; CheckmAb. ; CheckmAb. ; Daiichi-Sankyo. ; S.S. is an advisory board member; Daiichi-Sankyo. ; S.S. is an advisory board member; Menarini. ; Menarini. ; Merck. ; S.S. is an advisory board member; Merck. ; S.S. is an advisory board member; Seattle Genetics. ; Seattle Genetics. **A. Bardelli:** ; A.Bardelli served in a consulting/advisory role; Illumina. ; Illumina. ; Inivata. ; A.Bardelli served in a consulting/advisory role; Inivata. ; A.Bardelli is a member of the NeoPhore scientific advisory board. A.Bardelli is cofounder and shareholder of NeoPhore.; NeoPhore. ; NeoPhore.

**Status:** Complete

\*\*\*To log out, simply close your browser window. All information will be saved if you click the Save and Continue button after each step.

For assistance with login problems, please contact the [myAACR Helpdesk](#).

For assistance with technical problems related to the submitter, contact the [OASIS Helpdesk](#) or call (217) 398-1792.

If you have any policy questions related to the AACR Annual Meeting 2022, please contact the AACR [E-mail: [abstract@aacr.org](mailto:abstract@aacr.org); Phone: (215) 440-9300].

Feedback